Homocysteine Clearance in Hemodialysis

Rafael Castillo; Rafael de la Rosa; Susana Duran; Yolanda Baca; Ruth Gallegos; Margarita Martnez; Fernando Pern; Susana Pedrinaci; Juan Bravo

Nephro-Urology Monthly

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Homocysteine Clearance in Hemodialysis

Author(s):

Rafael Fernandez Castillo^1,*,

Rafael J. Esteban de la Rosa²,

Susana Ruiz Duran²,

Yolanda Baca²,

Ruth Fernndez Gallegos²,

Margarita Martnez²,

Fernando Pern²,

Susana Pedrinaci²,

Juan A. Bravo²

1Departments of Nephrology, Academic Medical Centre Virgen de las Nieves, rafaelfernandez@ugr.es, Spain

2Departments of Nephrology, Academic Medical Centre Virgen de las Nieves, Spain

Nephro-Urology Monthly:Vol. 2, issue 4; 561-566

Article type:Research Article

Received:Nov 24, 2009

Accepted:Jan 02, 2010

How to Cite:Rafael Fernandez CastilloRafael J. Esteban de la RosaSusana Ruiz DuranYolanda BacaRuth Fernndez GallegosMargarita MartnezFernando PernSusana PedrinaciJuan A. Bravoet al.Homocysteine Clearance in Hemodialysis.Nephro-Urol Mon.2(4):561-566.

Abstract

Background and Aims: Homocysteine is a sulphur amino acid derived from methionine. Epidemiological studies show an association between hyperhomocysteinemia and an increased cardiovascular risk, a fact that has also been confirmed in patients with chronic renal failure. This study, conducted in stage 5 chronic kidney disease patients, seeks to define the prevalence of hyperhomocysteinemia, evaluate the clearance of homocysteine with dialysis, and describe the frequency of the mutation in the mutilen-tetrahydrofolate reductase enzyme and its relationship with plasma levels of homocysteine.

Methods: The reduced percentage of homocysteine and clearance of urea were analysed every six months for seven years in patients on dialysis. Urea and total homocysteine in plasma were measured in each of these studies and the type of dialyser - low or high permeability - used and the dialysis duration was determined. A molecular study of the gene coding for mutilen-tetrahydrofolate reductase enzyme was carried out in a group of patients and any C-T point mutation at position 677 of this gene was investigated. Mutation was described as not present, heterozygous for this mutation or homozygous for lactation.

Results: Neither the average levels of homocysteine before and after dialysis or the reduction percentage of homocysteine varied with gender, although purification of urea was higher in women. Comparisons of homocysteine levels and percentage reduction in this ratio according to the ultra filtration of the dialyser used showed significant results. The molecular study of the gene in mutilen-tetrahydrofolate reductase enzyme showed that mutation was present in 54.8%: 45.2% with heterozygous polymorphism and 9.7% with homozygous.

Conclusions: Patients undergoing hemodialysis were found to have higher levels of urea and its clearance was greater with the higher the ratio of ultra filtration dialyser. Mutation of the gene in mutilen-tetrahydrofolate reductase enzyme was similar in our patients compared to the general population and had no impact on plasma levels of homocysteine.

Keywords

End Stage Renal Disease

Full Text

Full text is available in PDF

comments